Heron Therapeutics Inc vs Clear Secure Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Clear Secure Inc trades at $48.23 (market cap $5.28B). The key difference: Clear Secure Inc is far larger — about 83.3× Heron Therapeutics Inc's market cap, and Clear Secure Inc pays a 1.12% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | YOU | |
|---|---|---|
Market Cap | $63.41M | $5.28B |
Sector | Health | Technology |
52-Week High | $1.49 | $62.36 |
52-Week Low | $0.32 | $29.61 |
Enterprise Value | $161.31M | $4.43B |
Dividend Yield | — | 1.12% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Clear Secure (YOU) trades at $51.29, down 3.26% in 24 hours, with a bearish technical signal but strong fundamentals including 66.66% gross margins and 90.29% ROE. Recent Q2 2026 earnings beat estimates with EPS of $0.49 versus $0.40 expected, driven by double-digit revenue growth and record free cash flow. The company launched corporate memberships to expand its identity platform, enhancing business travel offerings.
Outlook is mixed: robust profitability and growth initiatives support upside, but high valuation (P/E 34.6) and technical weakness near support at $50 pose risks. Analyst consensus is balanced with 44% buy ratings, yet insider selling and competitive pressures require caution for near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →